Eikon Therapeutics, Inc.(EIKN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EIKN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Eikon Therapeutics, Inc. (EIKN), a Healthcare sector company. EIKN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Eikon Therapeutics, Inc. reports net income of $-83.0M, free cash flow of $-90.1M. Top institutional holders of EIKN by reported 13-F value include FMR, BlackRock,, Foresite Capital Management IV,, based on the most recent SEC filings. EIKN trades on the Nasdaq exchange and files with the SEC under CIK 1861123. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EIKN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eikon Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-83.0M
Free Cash Flow
Q1 2026
$-90.1M
ROIC
Q1 2026
-15.9%
AI Insight: EIKN Financial Trends
Single quarter of data only — no trend analysis possible; Eikon burned $90M in operating cash flow in Q1 2026 with no disclosed revenue.
• Operating loss of $87M and operating cash outflow of $90M in Q1 2026 reflect a pre-revenue, clinical-stage cost structure.
• Equity stood at $551M in Q1 2026, suggesting meaningful runway relative to the $90M quarterly cash burn.
⚠ At $90M quarterly cash burn with no revenue, equity of $551M implies roughly 6 quarters of runway — watch for capital raises.
⚠ Total debt is undisclosed; clarity on leverage structure is needed to assess true financial flexibility.
AI Insight: EIKN Ratio Trends
Single-quarter snapshot only — insufficient data to establish any financial trend for Eikon Therapeutics.
• Only one quarter of data available (Q1 2026); no multi-period comparison is possible.
• Q1 2026 ROA of -39.0% and ROIC of -63.4% indicate heavy asset consumption relative to returns.
⚠ ROE of -60.3% in Q1 2026 signals significant equity erosion — typical of pre-revenue biotech burn.
⚠ Operating margin, net margin, and D/E are unavailable; future disclosures needed to assess leverage and profitability trajectory.
Get alerted when EIKN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Eikon Therapeutics, Inc. including:
Top Institutional Holders of EIKN
FMR LLC
$40.6M3,836,830 shBlackRock, Inc.
$35.1M3,319,379 shForesite Capital Management IV, LLC
$20.6M1,943,682 shMerck & Co., Inc.
$17.6M1,666,666 shForesite Capital Management V, LLC
$14.0M1,318,983 shCapital World Investors
$12.1M1,143,637 shALLIANCEBERNSTEIN L.P.
$10.8M1,022,188 shVANGUARD CAPITAL MANAGEMENT LLC
$10.3M969,431 shEcoR1 Capital, LLC
$7.8M732,606 shBAKER BROS. ADVISORS LP
$5.9M555,555 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $40.6M | 3,836,830 |
| BlackRock, Inc. | $35.1M | 3,319,379 |
| Foresite Capital Management IV, LLC | $20.6M | 1,943,682 |
| Merck & Co., Inc. | $17.6M | 1,666,666 |
| Foresite Capital Management V, LLC | $14.0M | 1,318,983 |
| Capital World Investors | $12.1M | 1,143,637 |
| ALLIANCEBERNSTEIN L.P. | $10.8M | 1,022,188 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.3M | 969,431 |
| EcoR1 Capital, LLC | $7.8M | 732,606 |
| BAKER BROS. ADVISORS LP | $5.9M | 555,555 |
More Healthcare Companies
View all Healthcare →Put EIKN on your watchlist
Track score changes the day Eikon Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EIKN a good stock to buy?
13F Pro's AI-powered analysis of Eikon Therapeutics, Inc. (EIKN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EIKN are available on the EIKN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EIKN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EIKN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eikon Therapeutics, Inc.'s investment landscape.